secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-205600
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal submits resmetirom NDA for NASH; cash $298.4M as of June 30
--------------------------------------------------------------------

- Resmetirom NDA submitted to FDA for accelerated approval of NASH with liver fibrosis.
- Cash, cash equivalents and marketable securities $298.4M at June 30, 2023, down from $358.8M at Dec 31, 2022.
- Operating expenses for six months ended June 30, 2023: $164.8M (R&D $130.8M, G&A $34.0M), up from $127.9M in prior year.
- Interest income $7.3M and interest expense $5.2M for six months; cash used in operations $159.4M.
- ICER final report indicates resmetirom may be cost-effective for at-risk NASH; disease education campaigns launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523205600/0001193125-23-205600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523205600/d542332d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-205600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer